Target intelligence / Profile preview

OTU deubiquitinase 1 (OTUD1)

Target
OTUD1
Molecular classification
Enzyme, Deubiquitinating enzyme (DUB), Cysteine protease, OTU family
01

Overview

OTU deubiquitinase 1 (OTUD1) is a member of the OTU (ovarian tumor) family of cysteine proteases classified as a deubiquitinating enzyme (DUB). It specifically hydrolyzes K63-linked polyubiquitin chains, thereby regulating various signaling pathways including canonical NF-κB activation, interferon antiviral responses, apoptosis, necroptosis, and antioxidant mechanisms via KEAP1 binding. OTUD1's biological roles extend to ribosome quality control by deubiquitinating ribosomal protein RPS10/eS10, influencing mRNA stability and translation in cells, and enhancing iron transport through stabilization of IREB2. Aberrant OTUD1 function or expression is linked to cancer aggressiveness, inflammatory conditions, and neurodegenerative disease. While no drugs currently target OTUD1, it represents a promising therapeutic target due to its central role in controlling inflammation, cell death, and proteostasis

Other names
OTU domain-containing protein 1OTUD1DUBA7OTDC1OTU domain containing 1DUBA-7
02

Mechanism of action

Drugs (if developed) would likely inhibit or modulate OTUD1's deubiquitinating activity, affecting K63-linked ubiquitin chain hydrolysis, NF-κB signaling, and downstream apoptotic or inflammatory processes

03

Biological functions

Regulation of NF-κB signaling (suppression of canonical NF-κB activation)Antagonizing apoptosis and necroptosisUpregulation of interferon antiviral responseKEAP1-mediated antioxidant regulationRibosome quality control (regulates RPS10/eS10 deubiquitination)Regulation of iron transport (via IREB2 and transferrin receptor 1)
04

Disease associations

Cancer (differential expression in thyroid cancer)Inflammation (regulator in inflammatory bowel disease, hepatitis, sepsis)Oxidative stress/ROS-associated cell death (including oxeiptosis)Neurodegenerative diseases (Machado-Joseph disease, autosomal dominant cerebellar ataxia)
05

Safety considerations

Modulating deubiquitination may disturb cellular homeostasis, potentially leading to excess inflammation, cell death, or disrupted protein turnover (such as ribosome quality control)
06

Interacting drugs

None reported or established yet
07

Biomarkers

OTUD1 expression (diagnostic and prognostic indicator in thyroid cancer and potentially other inflammatory or oxidative stress-linked conditions)

Beyond the preview

Go deeper on OTU deubiquitinase 1 (OTUD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTU deubiquitinase 1 (OTUD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call